Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5406288 | 0.80 | HSD11B1 (0.50) | HSD11B1L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL5413875 | 0.80 | PKM (0.46) | HSD11B1L3MBTL1TGM2MEN1KMT2A | |
| SCHEMBL26229888 | 0.78 | TSHR (0.42) | MEN1KMT2ATHRBALDH1A1GAA | |
| SCHEMBL7127597 | 0.78 | HSD11B1 (0.43) | HSD11B1L3MBTL1MEN1KMT2ATHRB | |
| Acrylic Acid SCHEMBL29281853 | 0.77 | THRB (0.45) | HSD11B1L3MBTL1TGM2THRBCYP2C9 | |
| Water SCHEMBL10350218 | 0.76 | HSD11B1 (0.42) | HSD11B1L3MBTL1MEN1KMT2ATHRB | |
| SCHEMBL11760000 | 0.76 | ALDH1A1 (0.42) | HSD11B1L3MBTL1MEN1KMT2ATHRB | |
| SCHEMBL18433707 | 0.76 | P2RX7 (0.36) | HSD11B1L3MBTL1TGM2MEN1KMT2A | |
| SCHEMBL13764831 | 0.73 | TGM2 (0.48) | HSD11B1L3MBTL1TGM2MEN1KMT2A | |
| SCHEMBL3101322 | 0.72 | HSD11B1 (0.46) | HSD11B1L3MBTL1MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163659-A | Three-dimensional dynamic self-repairing photonic crystal hydrogel based on cyclodextrin inclusion and construction method thereof | 江苏大学 | 2022-03-11 | — | — | CN | claimed |
| US-12037679-B2 | Method of forming a diamond film | APPLIED MATERIALS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230279540-A1 | METHOD OF FORMING A DIAMOND FILM | APPLIED MATERIALS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279540-A1 | METHOD OF FORMING A DIAMOND FILM | APPLIED MATERIALS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| CN-114163659-A | Three-dimensional dynamic self-repairing photonic crystal hydrogel based on cyclodextrin inclusion and construction method thereof | 江苏大学 | 2022-03-11 | — | — | CN | disclosed |
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| CN-110563868-A | Polyester fatty enamide modified adamantane, corrosion-resistant and drag-reducing coating and preparation method thereof | 四川轻化工大学 | 2019-12-13 | — | — | CN | disclosed |
| US-9359277-B2 | Compositions and processes of preparing and using the same | PURDUE RESEARCH FOUNDATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO LTD (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785473-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-7598384-B2 | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-10-06 | — | — | US | disclosed |
| EP-1723116-B1 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008035049-A1 | ADAMANTANYL-(CYCLOPROPYL)-KETONES AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-03-27 | — | — | WO | disclosed |
| EP-1804781-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | Merz Pharma GmbH & Co.KGaA (DE) | 2007-07-11 | — | — | EP | disclosed |
| EP-1723116-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co. KGaA (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006037996-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-06 | — | — | US | disclosed |
| WO-2005082856-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-09 | — | — | WO | disclosed |
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | PMP22, ADCYAP1R1, CYP11B2 | HSD11B1 78/4885L3MBTL1 4412/4885TGM2 3861/4885 |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | HSD11B1 2009/4885L3MBTL1 2538/4885TGM2 1207/4885 |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | HSD11B1 2009/4885L3MBTL1 2538/4885TGM2 1207/4885 |
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | GRM5, GRIK5, GRIN2C | HSD11B1 4105/4885L3MBTL1 944/4885TGM2 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.